Results 211 to 220 of about 10,137,482 (392)
Saporin as a Commercial Reagent: Its Uses and Unexpected Impacts in the Biological Sciences-Tools from the Plant Kingdom. [PDF]
Ancheta LR+4 more
europepmc +1 more source
Book Review: Progress in the Biological Sciences in Relation to Dermatology − 2 [PDF]
P.D. Samman
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
The Cross Reference: An Invaluable Aid to Teaching and Research in the Biological Sciences [PDF]
John McMillin
openalex +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Bridging artificial intelligence and biological sciences: a comprehensive review of large language models in bioinformatics. [PDF]
Lin A+19 more
europepmc +1 more source
Food Science and Technology. Volume 2: Biological and Microbiological Aspects of Food. [PDF]
L R Shelton
openalex +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Amie J Dirks-Naylor+2 more
semanticscholar +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source